Abstract:Isonicotinic acid hydrazide (Isoniazid, INH) is one of the most commonly used first-line anti-tuberculosis drugs, which has been reported that the high concentration of INH in human body can lead to epilepsy, liver function failure, and even death. Therefore, studying the potential binding effects of INH on the structure and activity of human serum albumin (HSA) and catalase (CAT) is very essential for evaluating its toxicity and side effect. In this paper, multi-spectroscopic and molecular docking methods were used to elucidate the patterns of INH to HSA and CAT under imitated physiological conditions. The inner filter effect of all fluorescence data in the paper was eliminated to get accurate binding parameters. The Stern-Volmer quenching constants (KSV) of both HSA-INH system and CAT-INH system inversely correlated with temperatures, demonstrating that INH quench the intrinsic fluorescence of HSA and CAT via static quenching. The conformational investigation of HSA and CAT through UV-visible absorption spectroscopy, synchronous fluorescence and circular dichroism (CD) showed that INH could change the micro-environment of tryptophan residues and reduced the α-helix content of protein. These results demonstrated that the binding of INH may lead to the loosening of protein skeleton, which which may affect its physiological function. The results of molecular docking revealed that the INH was located in Sudlow’s site I of HSA. And INH bound to CAT at a cavity among the wrapping domain helical domain and β-barrel, which resulted in the inhibition of CAT activity. In addition, Levofloxacin (LVFX) is a new effective and safe second-line anti-tuberculosis drugs and can improve the curative effect on anti-TB by using with other anti-TB drugs, the result of Hill’s coefficients (nH) about synergy between INH and proved that LVFX promoted the interaction of HSA with INH. Moreover, according to the CD spectra, synergy between INH and LVFX changed the conformation of HSA and the amount of α-helix decreased about 7.9%. This work will provide important insights into the binding and toxicity mechanism of INH to HSA and CAT in vivo and is expected to be helpful in evaluating the essential information for using the INH safely.

A New Cocrystal of Isoniazid-Quercetin with Hepatoprotective Effect: the Design, Structure, and in Vitro/in Vivo Performance Evaluation

Cocrystallization with Syringic Acid Presents a New Opportunity for Effectively Reducing the Hepatotoxicity of Isoniazid.

Terahertz and Raman Spectroscopic Investigation of Monohydrate Cocrystal of Antitubercular Isoniazid with Protocatechuic Acid

A cocrystal for effectively reducing the hepatotoxicity of ethionamide

Protective Effects of Quercetin Against Pyrazinamide Induced Hepatotoxicity Via a Cocrystallization Strategy of Complementary Advantages

Preparation of quercetin-nicotinamide cocrystals and their evaluation underin vivoandin vitroconditions

Design and Applications of Bifunctional Cinnamide Derivatives As Potential Antimycobacterial Agents with Few Hepatotoxic Effects

Tuning the Pharmacokinetic Performance of Quercetin by Cocrystallization

Hepatoprotective Pyrazinamide–Baicalein Cocrystal with a Rare Ratio of 7:3

Hepatoprotective Bile Acid Co-Drug of Isoniazid: Synthesis, Kinetics and Investigation of Antimycobacterial Potential

Development of Quercetin-Phospholipid Complex to Improve the Bioavailability and Protection Effects Against Carbon Tetrachloride-Induced Hepatotoxicity in SD Rats.

Spectroscopic and Molecular Docking Study on Specific Binding and Inhibition of Isoniazid to Human Serum Albumin and Catalase.

Cocrystals of Isoliquiritigenin with Enhanced Pharmacokinetic Performance

Cocrystal of phloretin with isoniazid: preparation, characterization, and evaluation

Self-assembly of antifungal agent 5-fluorocytosine and nutrient trans-p-coumaric acid furnishes a cocrystallization clue with the potential to reduce toxicity and side effects for the drug: a case research of combining theory with experiment

Drug-Bridge-Drug Ternary Cocrystallization Strategy for Antituberculosis Drugs Combination

Hepatoprotective cocrystal of ethionamide: A new attempt to refurbish old drug through crystal engineering

Design and Synthesis of Isatin‐Tagged Isoniazid Conjugates with Cogent Antituberculosis and Radical Quenching Competence: In‐vitro and In‐silico Evaluations

Cocrystal of Sulfamethazine and P-Aminobenzoic Acid: Structural Establishment and Enhanced Antibacterial Properties

Quercetin attenuates NLRP3 inflammasome activation and apoptosis to protect INH-induced liver injury via regulating SIRT1 pathway

Cocrystals Of Propylthiouracil And Nutraceuticals Toward Sustained-Release: Design, Structure Analysis, And Solid-State Characterization